Researchers will soon undertake one of the largest-ever long-term clinical trials of a system designed to help regulate blood sugar levels of individuals with type 1 diabetes mellitus. If the ...

Mere weeks after announcing the first insulin pump partner for its FreeStyle Libre 2 Plus continuous glucose monitor—in which the “Plus” designates an FDA-cleared ability to link up with automated ...

A recent paper published in Diabetes Technology & Therapeutics describes the design, safety and basic efficacy of a device-agnostic smartphone app that can interface with continuous glucose monitors, ...

Hybrid closed-loop systems are increasingly gaining recognition as a gold-standard option for diabetes management, and medtech makers are jumping at the opportunity to add their own artificial ...

Adding advanced artificial intelligence (AI) to an artificial pancreas regulating type 1 diabetes is safe and improves the system’s efficiency, a first-of-its-kind study from UVA Center for Diabetes ...

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod ® Insulin Management System (OmniPod System), today announced a license agreement and partnership ...

When used in an appropriately trained and equipped clinic setting, supported open-source artificial pancreas systems (SOSAPS) are at least as safe and effective as retail APS, but with lower cost. An ...

Four studies backed by the National Institutes of Health have either launched or are poised to launch in the near future. Researchers hope these studies will serve as the potential bridge between ...

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-MKT: SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable ...

Several companies showed promising results for automated insulin delivery (AID) systems at the American Diabetes Association (ADA) annual meeting in New Orleans. Studies of the systems, also known as ...

CHICAGO (Reuters) - A test run of an "artificial pancreas" that monitors blood sugar and delivers both insulin and regulatory hormone called glucagon helped patients achieve near-normal blood sugar ...

A novel investigational fully automated "artificial pancreas" system that combines rapid-acting insulin aspart (Fiasp, Novo Nordisk) and pramlintide (Symlin, AstraZeneca) performed similarly to a ...